AKTS (Aktis Oncology) FCF Margin %: -808.68% (As of Mar. 2026)


AKTS Aktis Oncology Inc AKTS
9 GF Score
Price $31.15
! 3 Warning Signs
View Full Analysis

What is Aktis Oncology FCF Margin %?

Aktis Oncology AKTS +8.54% 9 FCF Margin % is -808.68% as of Mar. 2026. GuruFocus rates AKTS with a GF Score™ of 9/100. The stock has 3 warning signs investors should review. Among 959 Biotechnology companies, Aktis Oncology ranks worse than 72.47% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Aktis Oncology's Free Cash Flow for the three months ended in Mar. 2026 was $-26.10 Mil. Aktis Oncology's Revenue for the three months ended in Mar. 2026 was $3.23 Mil. Therefore, Aktis Oncology's FCF Margin % for the quarter that ended in Mar. 2026 was -808.68%.

As of today, Aktis Oncology's current FCF Yield % is -1.52%.

The historical rank and industry rank for Aktis Oncology's FCF Margin % or its related term are showing as below:

AKTS' s FCF Margin % Range Over the Past 10 Years
Min: -1134.54   Med: -167.14   Max: 800.27
Current: -511.99

During the past 4 years, the highest FCF Margin % of Aktis Oncology was 800.27%. The lowest was -1134.54%. And the median was -167.14%.

AKTS's FCF Margin % is ranked worse than
72.47% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs AKTS: -511.99

Aktis Oncology FCF Margin % Related Terms

Aktis Oncology FCF Margin % Historical Data

* Premium members only.

The historical data trend for Aktis Oncology's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aktis Oncology FCF Margin % Chart

Aktis Oncology Annual Data
Trend Dec22 Dec23 Dec24 Dec25
FCF Margin %
0.00 0.00 800.27 -1,134.54

Aktis Oncology Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial 0.00 -1,338.98 0.00 0.00 -808.68

AKTS vs OLMA, EYPT, ZBIO: FCF Margin % Comparison

For the Biotechnology subindustry, Aktis Oncology's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aktis Oncology FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aktis Oncology's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Aktis Oncology's FCF Margin % falls into.


AKTS
9GF Score
Aktis Oncology Inc AKTS
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aktis Oncology FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Aktis Oncology's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-73.711/6.497
=-1,134.54 %

Aktis Oncology's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-26.096/3.227
=-808.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -808.68% mean?
Aktis Oncology (AKTS) has a FCF Margin % of -808.68% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Aktis Oncology and its competitors. According to the industry distribution chart, Aktis Oncology ranks #695 out of 959 companies in the Biotechnology industry, placing it in the top 72.5%.
Is Aktis Oncology's FCF Margin % too high?
Aktis Oncology's current FCF Margin % is -808.68%. Based on the distribution chart, Aktis Oncology ranks #695 out of 959 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Aktis Oncology has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's FCF Margin % compare to OLMA and EYPT?
According to the Biotechnology industry distribution chart, Aktis Oncology ranks #695 out of 959 companies for FCF Margin %. This places Aktis Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Aktis Oncology and its competitors. Aktis Oncology's current FCF Margin % is -808.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current FCF Margin % of -808.68%. The current FCF Margin % is -808.68%. Aktis Oncology's overall GF Score™ is 9/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current FCF Margin % is -808.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aktis Oncology Business Description

Address 17 Drydock Avenue, Suite 17-401, Boston, MA, USA, 02210
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
9GF Score

Get the complete analysis for AKTS

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.15
Price